Sugi Predict

Sugi Predict / Compounds / SCHEMBL282513

SCHEMBL282513

SCHEMBL282513

COc1cc([N+](=O)[O-])ccc1S(=O)(=O)Cl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.58
▸ TRPV4 Q9HBA0 1/20 0.58
▸ ALPL P05186 2/20 0.53
▸ TDP1 Q9NUW8 1/20 0.53
▸ PKM P14618 1/20 0.49
▸ LMNA P02545 3/20 0.47
▸ POLB P06746 2/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ HPGD P15428 2/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ PTGS2 P35354 2/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ CYP19A1 P11511 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29800437 0.87 TDP1 (0.57) HTTTRPV4TDP1PKMLMNA
SCHEMBL3071086 0.87 TDP1 (0.57) HTTTRPV4TDP1PKMLMNA
SCHEMBL1098646 0.85 HTT (0.60) HTTALPLTDP1PKMLMNA
SCHEMBL2032272 0.84 HTT (0.63) HTTALPLTDP1PKMLMNA
SCHEMBL17373258 0.84 HTT (0.58) HTTALPLTDP1PKMLMNA
SCHEMBL38656746 0.84 HTT (0.63) HTTALPLTDP1PKMLMNA
SCHEMBL26116577 0.83 TRPV4 (0.56) HTTTRPV4TDP1LMNAPOLB
SCHEMBL3573840 0.83 HTT (0.57) HTTALPLTDP1PKMLMNA
SCHEMBL31195234 0.81 ALDH1A1 (0.61) HTTALPLTDP1PKMLMNA
SCHEMBL31195232 0.81 ALDH1A1 (0.61) HTTALPLTDP1PKMLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109516987-B Preparation method of avibactam intermediate 江西富祥药业股份有限公司 2020-07-24 — — CN claimed
CN-104678028-A Pretreatment and detection method for biogen amine neurotransmitter and detection kit INST PHARM & TOXICOLOGY AMMS 2015-06-03 — — CN claimed
WO-2026104812-A1 RAB27 INHIBITORS IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2026-05-21 — — WO disclosed
EP-4719413-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF Animol Discovery, Inc. (US) 2026-04-08 — — EP disclosed
US-20260092070-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF ANIMOL DISCOVERY INC (US) 2026-04-02 — — US disclosed
EP-4687885-A2 PREVENTION/TREATMENT OF ISCHEMIC REPERFUSION INJURY Rev Therapeutics (US) 2026-02-11 — — EP disclosed
US-12233081-B2 Hygromycin a compounds and methods of treating spirochete diseases NORTHEASTERN UNIVERSITY (US) 2025-02-25 — — US disclosed
EP-4496569-A1 CXCR6 SULFONAMIDE COMPOUNDS ChemoCentryx, Inc. (US) 2025-01-29 — — EP disclosed
EP-4486453-A1 BENZAMIDE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS F. Hoffmann-La Roche AG (CH) 2025-01-08 — — EP disclosed
US-20250000883-A1 TREATING NEUROINFLAMMATORY CONDITIONS AN2 THERAPEUTICS, INC. (US) 2025-01-02 — — US disclosed
WO-2024246837-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF ANIMOL DISCOVERY, INC. (US) 2024-12-05 — — WO disclosed
US-5773612-A VASOPRESSIN OR OXYTOCIN RECEPTORS SANOFI (FR) 1998-06-30 — — US disclosed
US-5728723-A ANTIDIURETIC AND OXYTOCIN RECEPTORS SANOFI (FR) 1998-03-17 — — US disclosed
US-5726322-A 1-benzenesulfonyl-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present SANOFI (FR) 1998-03-10 — — US disclosed
US-5686624-A 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present SANOFI (FR) 1997-11-11 — — US disclosed
US-5663431-A CHEMICAL INTERMEDIATES SANOFI (FR) 1997-09-02 — — US disclosed
US-5594023-A 1,3-dihydroindol-2-one derivatives substituted in the 3-position by a nitrogen-containing group, their preparation and the pharmaceutical compositions in which they are present SANOFI (FR) 1997-01-14 — — US disclosed
US-5585394-A INHIBITOR, ANTAGONIST OF VASOPRESSIN OR OXYTOCIN SANOFI (FR) 1996-12-17 — — US disclosed
US-4211776-A ANTIEMETICS CHOAY S.A. (FR) 1980-07-08 — — US disclosed
US-4132786-A ANTIEMETICS, ANTICONVULSANTS, ANESTHETICS, ANTIBIOTICS MOREAU ROBERT C 1979-01-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12233081-B2 Hygromycin a compounds and methods of treating spirochete diseases TREH, GBA1, HSP90AB1 HTT 24/4885TRPV4 1753/4885ALPL 2024/4885
US-20260092070-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF JAK1, JAK3, JAK2 HTT 3902/4885TRPV4 2217/4885ALPL 1034/4885
US-20250000883-A1 TREATING NEUROINFLAMMATORY CONDITIONS MAPT, IL1B, IL6 HTT 12/4885TRPV4 1105/4885ALPL 2210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.